Vivos Therapeutics (NASDAQ: VVOS)ย is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (โOSAโ) in adults). The company today announced it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, March 28, 2024. In addition, at 5 p.m. ET on March 28, the company will conduct a conference call to review the results and provide an overview of Vivosโ recent milestones and developments. Interested parties should dial (888) 886-7786 or (416) 764-8658 (international) and enter passcode 27185528 to access the call. A replay and live and archived webcast of the conference call will be available as detailed in the announcement.
To view the full press release, visitย https://ibn.fm/HXR80
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (โOSAโ) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating adult mild to severe OSA. It has proven effective in over 42,000 patients treated worldwide by more than 1,900 trained dentists. The Vivos Method includes treatment regimens that employ proprietary appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patientโs upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with adult mild to severe OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (โVIPโ) program offers dentists training and other value-added services in connection with using The Vivos Method.
NOTE TO INVESTORS:ย The latest news and updates relating to VVOS are available in the companyโs newsroom atย http://ibn.fm/VVOS
About InvestorWire
InvestorWireย (โIWโ) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visitย https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:ย https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered byย IBN
